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Abstract: A simple and effective colorimetric method for the detection of normetanephrine (NMN), 
an O-methylated metabolite of norepinephrine, using functionalised gold nanoparticles is 
described. This metabolite is an important biomarker in the diagnosis of adrenal tumours such as 
pheocromocytoma or paraganglioma. The colorimetric probe consists of spherical gold 
nanoparticles (AuNPs) functionalized with two different ligands, which specifically recognize 
different functional groups in normetanephrine. Thus, a benzaldehyde-terminated ligand was 
used for the recognition of the amino alcohol moiety in NMN, by forming the corresponding 
oxazolidine. On the other hand, N-acetyl-cysteine was chosen for the recognition of the phenolic 
hydroxyl group through the formation of hydrogen bonds. The selective double molecular 
recognition between the probe and the hydroxyl and the amino-alcohol moieties of 
normetanephrine led to interparticle-crosslinking aggregation resulting in a change in the color of 
the solution, from red to blue, which could be observed by naked eye. The probe was highly 
selective towards normetanephrine and no color changes were observed in the presence of other 
neurotransmitter metabolites such as homovanillic acid (HVA) (dopamine metabolite), 5-
hydroxyindoleacetic acid (5-HIAA) (serotonin metabolite), or other biomolecules present in urine 
such as glucose (Glc), uric acid (U.A), and urea. Finally, the probe was evaluated in synthetic 
urine with constituents that mimic human urine, where a limit of detection of 0.5 µM was achieved.  
 




Normetanephrine (NMN) is an O-methylated metabolite of norepinephrine produced by 
the enzyme catechol-O-methyltransferase within tumours. This metabolite is one of the most 
useful biomarkers for the early diagnostic of neuroendocrine tumours such as 
pheochromocytomas and paragangliomas (PPGL) [1-3]. These tumours, which cause 
hypertension and occur with headaches, excessive sweating and palpitations, arise from the intra-
adrenal and extra-adrenal chromaffin cells, and are characterized by an overproduction of 
catecholamines, which result in increased levels of their O-methylated metabolites in plasma or 
urine, being NMN the metabolite found in the highest concentration [4]. Measurements of NMN 
levels in plasma or urine are recommended for first line biochemical diagnosis of PPGL [5-6].  
Some analytical methods such as electrochemistry [7], radioimmunoassays [8-9], 
enzyme-linked immunosorbent assay (ELISA) [10], high performance liquid chromatography with 
tandem mass spectrometry (HPLC-MS) [11-14] with fluorogenic detection (HPLC-FD) [15-16] and 
with electrochemical detection (HPLC-ED)[17-19] have been developed for the quantification of 
NMN in human plasma and urine. However, the application of these techniques requires of 
sophisticated and expensive equipment, in addition to their complicated sample-preparation and 
professional operation. Due to the limitations of the above-mentioned analytical methods and the 
importance of the determination of NMN for the diagnosis of PPGL, the development of simple 
analytical techniques that can be readily applied to the measurement of NMN in clinical samples 
is of high interest. Colorimetric probes are especially appealing as sensing devices because there 
are few techniques as simple as visual detection and they allow rapid and sensitive determination 
to the naked eye, on site, without any sample pre-treatment. However, to the best of our 
knowledge, the only colorimetric assay for NMN detection is based on the Pisano colorimetric 
method, which measures the total content of metanephrines (normetanephrine and 
metanephrine) in urine, after their conversion into vanillin through oxidation using periodate. This 
method is non-specific, and involves lengthy separations and sample pre-treatment [20-22]. 
In recent years, spherical gold nanoparticles have received great attention as platforms 
in the development of colorimetric sensors and probes. AuNPs have wonderful optoelectronics 
properties [23-24]. In particular the surface plasmon resonance (SPR) band, which can be 
modified upon the analyte–induced aggregation of the nanoparticles. This modification in the SPR 
band results in a color change from red (dispersed AuNPs) to blue (aggregated AuNPs) which 
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can be observed by naked eye. Other great advantages are their good biocompatibility and ease 
of surface functionalisation with different organic molecules. Thus, numerous selective and 
sensitive colorimetric probes based on functionalised AuNPs, which allow the selective 
determination of different types of analytes at very low concentrations, have been reported [25-
28]. 
Taking into account the above mentioned facts, we present herein a novel approach for 
the fast, simple and selective determination of normetanephrine in water and in simulated urine, 
based on the use of bifunctionalised gold nanoparticles. Probe GNP1 consists of spherical gold 
nanoparticles functionalised with two different moieties: a benzaldehyde-terminated ligand (L1) 
which can react with the aminoalcohol group of NMN to give the corresponding oxazolidine [29], 
and N-acetylcysteine (L2), which binds the phenolic hydroxyl group through the formation of 
hydrogen bonds, and is also a good stabilizer of gold nanoparticles due to its carboxylate group 
[30-31]. This double molecular interaction with NMN leads to aggregation of the nanoparticles, 
resulting in a strong bathochromic shift of their SPR band and a color change of the solution from 






Scheme 1. Sensing paradigm of the colorimetric detection of normetanephrine (NMN) based on the aggregation of gold 









Gold (III) chloride hydrate (HAuCl4·3H2O) 99.995%, sodium citrate dihydrate, N-Acetyl-L-cysteine 
≥99% (L2), (±)-α-lipoic acid ≥98.0%, 4-hydroxybenzaldehyde  98%, N,N'-
dicyclohexylcarbodiimide (DCC) 99%, 4-dimethylaminopyridine (DMAP) ≥99%, homovanillic acid 
(HVA) ≥99.0%, 5-Hydroxyindole-3-acetic acid (5-HIAA) ≥98%, D-(+)-Glucose (Glc) ≥99.5%, uric 
acid (U.A) ≥99%, urea 98% and surine negative urine, were purchased from Sigma Aldrich and 
used without further purification. All the aqueous solution were prepared with Mili-Q water (18.2 
MΩ cm-1). 
2.2. General Methods 
UV-Vis absorption spectra were recorded using a 1 cm path length quartz cuvette on a Shimadzu 
UV-2101PC spectrophotometer. All measurements were carried out at room temperature. To 
characterize the induced aggregation of the gold nanoparticles probe in the presence of 
normetanephrine, high-resolution transmission electron microscopy (JEOL-1010 transmission 
electron microscopy operating at 100 kV) was used. Z potential and DLS values were measured 
in a Malvern Zetasizer ZS, for 3 times in 10-25 cycles. To verify the gold nanoparticles 
functionalization Fourier-transform infrared spectra were recorded with a Cary 630 FT-IR 
spectrometer within the wavenumber range of 648-4000 cm-1 at a resolution of 8 cm-1. To confirm 
the structure of ligand L1 1H-NMR and 13C-NMR spectra were recorded with a Bruker DRX-300 
Spectrometer (300 MHz, 128 scans). Chemical shifts are reported in ppm with tetramethylsilane 
as an internal standard. 
2.3 Synthesis of 4-(liponyloxy)benzaldehyde (L1) 
4-(Liponyloxy)benzaldehyde (L1) was synthesized as previously reported [35] from (±)-α-lipoic 
acid (0.75 g, 3.63 mmol), 4-hydroxybenzaldehyde (0.44 g, 3.63 mmol), DCC (0.75 g, 3.63 mmol) 
and a catalytic amount of DMAP (0.04 g, 0.33 mmol) in anhydrous CH2Cl2 (10 mL). L1 was 
obtained as a yellow oil in 86% yield. 
1H NMR (300 MHz, CDCl3) δ 9.98 (s, 1H), 7.91 (d, J = 9.0, 2H), 7.26 (d, J = 9.0, 2H), 3.61–3.57 
(m, 1H), 3.22 – 3.09 (m, 2H), 2.60 (t, J = 7.4 Hz, 2H), 2.51 – 2.42 (m, 1H), 1.97 – 1.88 (m, 1H), 
1.84 – 1.67 (m, 4H), 1.63 – 1.52(m,2H). 13C NMR (75 MHz, CDCl3) δ 190.96, 171.71, 155.35, 
134.39, 131.25, 122.51, 56.53, 40.51, 38.79, 34.94, 34.21, 28.64, 24.77.  
2.4 Synthesis of probe GNP1 
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First, citrate-coated AuNPs with a diameter ca. 17 nm were synthesized as reported previously 
[32-34]. Briefly, 5 mL of 13.6 mM aqueous trisodium citrate solution were added to an aqueous 
boiling solution of HAuCl4 (95 mL, 0.23 mM) and the resulting mixture was kept continuously 
boiling for 30 min until a red solution was obtained. The solution was cooled to room temperature, 
and then the mixture was purified by filtration through a 0.22 µM membrane and the filtrate was 
then stored in a refrigerator at 4°C until use. 
Probe GNP1 was prepared from the previously synthesized citrate-capped AuNPs (ca. 17 nm) by 
a stepwise ligand-exchange reaction. Thus, 20 µl of L2 1 mM in DMF were added to 10 mL of the 
as-prepared citrate capped AuNPs. After stirring for 1 min at room temperature, 20 µl of L1 1 mM 
in DMF were added. The solution was stirred 5 h at room temperature. To purify GNP1, the 
mixture was centrifuged for 10 min at 11,000 rpm, the supernatants were decanted and the 
nanoparticles redispersed in Mili-Q water (10 mL). This procedure was repeated twice.  
2.5 Synthesis of probe GNP2 
GNP2 nanoparticles were synthesized following the same procedure as GNP1. First, citrate-
coated AuNPs of ca. 34 nm were prepared, following the process mentioned above, but in this 
case, using 5 mL of 3.4 mM aqueous trisodium citrate solution. Probe GNP2 was obtained by the 
stepwise addition of L2 and L1 to the as-synthesized citrate-capped AuNPs using the same 
amounts and the same procedure as described above for GNP1.  
 
2.6 Sensing and selectivity studies 
For the UV-vis titration experiments, aqueous solutions of normetanephrine of different 
concentrations at pH 7 (phosphate buffer 10 mM) were freshly prepared. Then, 200 μL of GNP1 
(8.12 X 10-10 M) and 200 μL of the NMN solution at an appropriate concentration (0–24 mM) were 
mixed to obtain a final volume of 400 μL. As an example, 400 μL of a solution containing GNP1 
4.06 X 10-10 M and NMN 5 mM were obtained by mixing 200 μL of GNP1 and 200 μL of NMN 10 
mM. Samples were incubated at room temperature for 6 min before recording the corresponding 
UV-vis spectra. The same procedure was followed to evaluate the sensing ability of GNP2 (NMN 
final concentrations of 1, 6 and 10 mM). The selectivity studies were performed following the same 
procedure by mixing 200 μL of GNP1 (8.12 X 10-10 M) and 200 μL of an aqueous buffered solution 
(pH = 7) of the studied interferent (10 mM). A competitive study was performed by adding 200 μL 
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of an aqueous buffered solution containing a mixture of NMN and all the interferents (10 mM 
each) to 200 μL of GNP1. The titration experiments with optimized probe (OGNP1) were 
conducted as follows: OGNP1 was freshly prepared by adding 20 μL of NMN 80 mM to 200 μL of 
the GNP1 solution, and incubating the mixture for 1 min at room temperature. Then, 180 μL of 
the NMN sample solution at an appropriate concentration (0–20 μM) were added to the OGNP1 
solution to obtain a final volume of 400 μL. Samples were incubated for 6 min before taking 
measurements in the spectrophotometer. Measurements in simulated urine were made using 
SurineTM Negative Urine Control, that is rugged non-biological urine with constituents that mimic 
human urine, but without human urine´s research impediments. In a typical experiment, 200 μL 
of OGNP1 were mixed with 200 μL of NMN solutions in 20% Surine Negative Urine Control, 
incubated for 6 min, and analysed by UV-vis spectrophotometry. 
3. Results and Discussion 
3.1 Synthesis and characterization of GNP1 
Compound L1 was obtained through Steglich esterification of lipoic acid with 4-
hydroxybenzaldehyde using as a coupling agent DCC and DMAP as a catalyst [35]. On 
the other hand, citrate-capped AuNPs were prepared by the Turkevich-Frens method wich 
consist in the reduction of tetrachloroauric acid with trisodium citrate in boiling water [32-
34]. Addition of L1 and L2 (1:1 molar ratio) to the citrate-stabilized AuNPs led to the 
formation of probe GNP1 through ligand exchange reactions, due the highly stable S-Au 
interactions. The functionalised gold nanoparticles were purifed by repeated centrifugation 
and redispersion in water to yield a red colored solution. 
 Probe GNP1 was characterized by UV-vis spectroscopy, transmission electron 
microscopy (TEM), dynamic light scattering (DLS) and infrared spectrospcopy (FTIR). The 
aqueous dispersions of GNP1 showed the typical SPR band at 523 nm in the UV-vis 
spectrum, in accordance with the values observed for dispersed AuNPs with sizes smaller 
than 25 nm [36-37]. The average size of the nanoparticles turned out to be of 17 nm from 
TEM measurements (Figure S1 C). Regarding the hydrodynamic diameter of the 
dispersed nanoparticles DLS showed an increase from 28 nm for citrate-stabilized AuNPs 
to 30 nm for GNP1 (Figure S2). The zeta-potential value of the GNP1 nanoparticles in 
aqueous solution was -30.6 mV. Finally, the ligand exchange was confirmed by FTIR, 
showing bands characteristic of L1 and L2 (Figure S4). The concentration of GNP1 probe 
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solution was calculated to be ca. 6 x 10-10 M by UV-vis spectroscopy considering an 
estimated molar extinction coefficient of ε = 6.01 x 108 M-1 cm-1 [38]. The red colored 
aqueous dispersion of GNP1 remained stable in the refrigerator for more than a month, 
with no observable changes in color nor in its SPR band. Furthermore, to evaluate the 
influence of the size of the nanoparticles in the sensitivity towards NMN, probe GNP2 was 
prepared from citrate-capped AuNPs of ca. 34 nm and ligands L1 and L2 following the 
same procedure as for GNP1, resulting in stable red suspensions (see Supp. Info). Citrate-
capped AuNPs of ca. 42 nm were also prepared. However, all attempts of functionalizing 
these nanoparticles with L1 and L2 resulted in their aggregation. 
 
3.2 Sensing ability of GNP1 towards normetanephrine 
GNP1 sensing capabilities were evaluated in the absence and presence of NMN (5 mM) 
at pH 7 (phosphate buffer, 10 mM). In the absence of NMN the aqueous suspension of 
GNP1 remained red with its characteristic SPR band at 523 nm in the UV-vis spectrum. 
However, in presence of excess NMN the red color changed progressively to blue within 
minutes, and the corresponding UV-vis spectrum showed a shift in the SPR band from 
523 nm to 612 nm, indicating the aggregation of GNP1 induced by NMN. This aggregation 
was further confirmed by TEM (Figure S1 A and B, corresponding to dispersed and 
aggregated nanoparticles) and DLS studies. The latter shows that in the presence of NMN 
the hydrodynamic radius of the particles increases from 30 nm to 450 nm (see Figure S3 
A and B). The zeta potential reduced from -30.6 mV (GNP1) to -9.35 mV (GNP1 + NMN). 
In addition, UV-vis kinetic studies confirmed a significant increase in the absorbance at 
612 nm of GNP1 in the presence of NMN, starting at the first minute, and reaching its 





Figure 1. UV-Vis spectra of GNP1 in the absence (red) and presence of NMN (5 mM) (blue) at pH 7 (phosphate buffer, 
10 mM). 
 
3.3 Selectivity evaluation of GNP1 in the presence of possible interferents   
Selective and sensitive detection of NMN plays a key role in the diagnosis of tumors such 
as pheochromocytoma. Selectivity features of GNP1 were evaluated in presence of other 
neurotransmitter metabolites such as, homovanillic acid (HVA, a dopamine metabolite) 
and 5-hydroxyindoleacetic acid (5-HIAA, a serotonin metabolite), and other biomolecules 
present in urine such as glucose (Glc), uric acid (U.A) and urea. After the addition of 
excess (5 mM final concentration) of the potential interferents to GNP1, negligible changes 
in the A612/A523 ratio (A612 = absorbance at 612 nm, A523 = absorbance at 523 nm), nor in 
the color of the solutions were observed (see Figure 2a and 2b and Figure S6). Moreover, 
in a competitive experiment, the addition of a mixture containing NMN and all the 
interferents (HVA, 5-HIIA, Glc, U.A and urea) to GNP1 led to a response similar to that 
found when only NMN is added to GNP1, (Figure 2b). All these data indicate that GNP1 
is able to selectively detect NMN in aqueous media in the presence of other 





Figure 2. Response of GNP1 in the presence of different molecules (5 mM) at pH 7 (phosphate buffer, 10 mM). a) Vials 
with the different tested molecules. b) Representation of A612/A523 for NMN and the interferents. Error bars correspond to 
the s. d. from three independent experiments. 
 
3.4 Sensitivity studies and optimization of GNP1 
In order to evaluate the influence of the size of the nanoparticles in the sensitivity, the response 
of GNP1 (17 nm) and GNP2 (34 nm) in front of NMN (1, 6 and 10 mM) was compared by UV-vis 
spectroscopy. As observed in Fig S8 and S9, GNP1 showed a higher sensitivity than GNP2. Thus, 
all experiments were performed with GNP1. In order to determine the sensitivity of the response 
of GNP1 towards NMN, UV-vis titration experiments in the presence of increasing concentrations 
of NMN (from 0 to 12 mM) were undertaken. As the concentration increased, a gradual change 
in the color of the nanoparticles is clearly observed, changing from red to purple and finally to 
blue (Figure 3a). Moreover as the amount of NMN increases a shift in the SPR band from 523 nm 
(dispersed nanoparticles) to 612 nm (aggregated) was observed by UV-vis (Figure 3b), confirming 
in this way the sensing protocol based on the NMN-induced aggregation of GNP1. As seen in 
Figure 4, a remarkable increase in the A612/A523 ratio was observed in the 4–10 mM concentration 
range, indicating a higher sensitivity of the probe within these NMN concentration values. 
Consequently, the sensitivity of the probe towards NMN detection could be improved by the 
addition of certain amount of NMN (to yield a final concentration of 4 mM) to the stock solution of 
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GNP1 before use [39]. Figure 5 shows clearly how the sensitivity towards NMN of this optimized 
probe (OGNP1) increases with respect to the sensitivity of GNP1 in the 0–10 µM range (Figure 
5, curves a and b). The limit of detection (LOD), calculated from the plot of A612/A523 vs NMN 
concentration in this low concentration range, was 4.7 µM for GNP1, and as low as 0.2 µM for 
OGNP1. This LOD confers our system a competitive basis for the detection of NMN at relevant 
clinical concentration. In particular, reported studies have determined that for normotensive 
patients, NMN levels above the normal range of 0.15 to 3.05 µM in urine can be indicative of 
pheochromocytoma and paraganglioma tumours [40]. 
 
Figure 3. a) Colour modulation of GNP1 when NMN was added at concentrations of 0, 3, 4, 5, 6, 7, 8, 9, 10, 11 mM (1-
10, respectively). b) Changes in the UV-Vis spectra of probe when NMN was added at concentrations of 0, 0.5, 1, 2, 3, 4, 






Figure 4. Plot of A612/A523 versus NMN concentration (0-12 mM) obtained with GNP1. Error bars correspond to 










Figure 5. Plots of A612/A523 versus NMN concentration within the 0-10 µM range for:  a) optimized probe OGNP1; 





3.5 Evaluation of OGNP1 sensitivity in urine 
In order to evaluate the sensing capabilities of GNP1 in real samples, assays in synthetic 
urine were performed. OGNP1 present a similar behaviour in urine [41] to that described 
above in aqueous media when increasing concentrations of NMN were added (Figure S7). 
From the A612/A523 vs NMN concentration plots, a linear response in urine within the 0 to 
10 µM NMN concentration range was observed, and a LOD of 0.52 µM was determined in 
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4. Conclusions  
In conclusion, we present herein a simple, fast¸ selective and sensitive colorimetric method 
for the detection of normetanephrine, a pheochromocytoma-biomarker, using aqueous 
dispersions of spherical gold nanoparticles bifunctionalised with 4-
(liponyloxy)benzaldehyde and N-acetylcysteine (GNP1). The presence of NMN induces 
the aggregation of the nanoparticles due to a double recognition process, which results in 
a clear colour change of the solution from red to blue, easily observed by naked eye, and 
a remarkable shift in the SPR band in the UV-vis spectrum. Selectivity essays in presence 
of other neurotransmitter metabolites such as homovanillic acid (HVA, a major 
catecholamine metabolite), 5-hydroxyindoleacetic acid (5-HIAA, a serotonin metabolite), 
and of other biomolecules present in urine such as glucose (Glc), uric acid (U.A), and urea, 
were performed. Only in the presence of NMN, a remarkable color change and UV-vis 
response was observed, demonstrating the high selectivity of the system. Regarding the 
sensitivity of the probe, a linear response within the 0-10 µM NMN concentration range 
and a LOD as low as 0.2 µM were determined in aqueous media with OGNP1. A similar 
response of the optimized probe to NMN was observed in synthetic urine, with a LOD of 
0.52 µM. We think that probe GNP1 can be a simple and effective alternative to determine 
NMN in aqueous media and urine, contributing to the early diagnosis of 
pheochromocytoma and paraganglioma tumours. 
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